Glucokinase MODY and Implications for Treatment Goals of Common Forms of Diabetes

Current Diabetes Reports

Volumn 14, Issue 12, 2014, Pages 1-7

  Ajjan, Ramzi A ^a,b   Owen, Katharine R ^c,d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

Cardiovascular disease; GCK MODY; Glucokinase MODY; Glycaemic targets; HbA1c; Microvascular complications; Postprandial glucose excursion

Indexed keywords

GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CLINICAL PRACTICE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; RETINOPATHY; REVIEW; TREATMENT PLANNING; BIOLOGICAL MODEL; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY; GENETICS; MOLECULARLY TARGETED THERAPY; MORTALITY; MOTIVATION;

DIABETES MELLITUS, TYPE 2; GLUCOKINASE; GOALS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY;

EID: 84910107184     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0559-0     Document Type: Review

References (41)

1. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117(15):1945–54.
2. Kahn MB, Cubbon RM, Mercer B, Wheatcroft AC, Gherardi G, Aziz A, et al. Association of diabetes with increased all-cause mortality following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in the contemporary era. Diabetes Vascul Dis Res: Off J Int Soc Diabetes Vascul Dis. 2012;9(1):3–9.
3. van Straten AH, Soliman Hamad MA, van Zundert AA, Martens EJ, Schonberger JP, ter Woorst JF, et al. Diabetes and survival after coronary artery bypass grafting: comparison with an age- and sex-matched population. Eur J Cardio-Thoracic Surg: Off J Eur Assoc Cardio-Thoracic Surg. 2010;37(5):1068–74.
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.
5. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.
7. Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.
8. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.
9. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.
10. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34 Suppl 2:S132–7.
11. Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. New Engl J Med. 1993;328(10):697–702.
12. Hattersley AT, Turner RC, Permutt MA, Patel P, Tanizawa Y, Chiu KC, et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet. 1992;339:1307–10.
13. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ. 2011;343:d6044.
14. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504–8.
15. Gloyn AL, van de Bunt M, Stratton IM, Lonie L, Tucker L, Ellard S, et al. Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia. Diabetologia. 2009;52(1):172–4.
16. Feigerlova E, Pruhova S, Dittertova L, Lebl J, Pinterova D, Kolostova K, et al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr. 2006;165(7):446–52.
17. Chakera AJ, Spyer G, Vincent N, Ellard S, Hattersley AT, Dunne FP. The 0.1 % of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort. Diabetes Care. 2014;37(5):1230–6.
18. Velho G, Froguel P, Clement K, Pueyo ME, Rakotoambinina B, Zouali H, et al. Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet. 1992;340(8817):444–8.
19. Byrne MM, Sturis J, Clement K, Vionnet N, Pueyo ME, Stoffel M, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Investig. 1994;93(3):1120–30.
20. Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njolstad PR, Hansen T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2002;45(3):427–35.
21. Steele AM, Wensley KJ, Ellard S, Murphy R, Shepherd M, Colclough K, et al. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. PLoS ONE. 2013;8(6):e65326. A useful article which reports the range of fasting plasma glucose and HbA1c seen in a large group of UK individuals with glucokinase mutations and suggests a reference range for HbA1c to help is identifying cases.
22. Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia. 2014;57(1):54–6.
23. Sagen JV, Bjorkhaug L, Molnes J, Raeder H, Grevle L, Sovik O, et al. Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry. Pediatr Diabetes. 2008;9(5):442–9.
24. Velho G, Blanche H, Vaxillaire M, Bellanne-Chantelot C, Pardini VC, Timsit J, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia. 1997;40:217–24.
25. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA: J Am Med Assoc. 2014;311(3):279–86. A well-performed study examining the prevalence of vascular complications in patients with GCK-MODY. Standardised methods were used to assess patients and compare to family controls and young-onset type 2 diabetes. This study confirms the many anecdotal reports that vascular complications are found at very low levels in GCK-MODY.
26. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308(6940):1323–8.
27. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care. 1997;20(5):785–91.
28. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34(1):145–50. Demonstrates the glycaemic thresholds (fasting glucose, 2 hr OGTT plasma glucose and HbA1c) for developing retinopathy in a very large data-pooling study including over 44000 individuals.
29. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81–90.
30. Organisation WH. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. 2011.
31. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. Diabetes Care. 2011;34 Suppl 2:S184–90.
32. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care. 1999;22(5):696–9.
33. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care. 2005;28(11):2626–32.
34. Decode Study Group EDEG. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26(3):688–96.
35. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481–9. Used real-world data from the UK General Practice Research Database to demonstrate that an HbA1c below 6.7 % is associated with a higher mortality than those with moderately raised HbA1c (up to 9.9 %).
36. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–92. Useful summary of the recent large trials of intensive control in type 2 diabetes and the implications for management.
37. Elwen FR, Huskinson AC, Bottomle MJ, Heller S, James C, Baxter PD, et al. One year mortality in individuals with diabetes following severe hypoglycaemia requiring emergency services intervention. Diabet Med. 2014;31(S1):26–7.
38. Mannucci E, Monami M, Lamanna C, Adalsteinsson JE. Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetol. 2012;49(4):307–14.
39. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–87.
40. Fendler W RM, Borowiec M, Malachowska B, Antosik K, Szadkowska A, Banach M, Urbanska-Kosinska M, Szopa M, Malecki M, Mlynarski W. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetol. 2014;in press.
41. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care. 2003;26(11):2999–3005.